Stephenson DT[au] - Search Results

Year	Number of Results
1987	1
1988	2
1989	1
1990	1
1991	1
1992	4
1993	1
1994	1
1995	2
1996	3
1997	4
1998	2
1999	1
2002	1
2005	3
2006	3
2007	1
2008	1
2009	2
2011	2
2012	4
2013	2
2017	1
2018	2
2020	2
2021	1
2023	1

1

Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments.

Arnerić SP, Kern VD, Stephenson DT. Arnerić SP, et al. Among authors: stephenson dt. Biochem Pharmacol. 2018 May;151:291-306. doi: 10.1016/j.bcp.2018.01.043. Epub 2018 Feb 1. Biochem Pharmacol. 2018. PMID: 29410157 Free article. Review.

2

Neuroimaging of pain: advances and future prospects.

Stephenson DT, Arneric SP. Stephenson DT, et al. J Pain. 2008 Jul;9(7):567-79. doi: 10.1016/j.jpain.2008.02.008. Epub 2008 May 2. J Pain. 2008. PMID: 18455479 Review.

3

Medically unexplained physical symptoms in emergency medicine.

Stephenson DT, Price JR. Stephenson DT, et al. Emerg Med J. 2006 Aug;23(8):595-600. doi: 10.1136/emj.2005.032854. Emerg Med J. 2006. PMID: 16858088 Free PMC article. Review.

4

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

Kruizinga MD, Stuurman FE, Exadaktylos V, Doll RJ, Stephenson DT, Groeneveld GJ, Driessen GJA, Cohen AF. Kruizinga MD, et al. Among authors: stephenson dt. Pharmacol Rev. 2020 Oct;72(4):899-909. doi: 10.1124/pr.120.000028. Pharmacol Rev. 2020. PMID: 32958524 Review.

5

Killing pain, not neurons.

Sahagan BG, Stephenson DT, Hounslow N, Liston DR, Manning PT. Sahagan BG, et al. Among authors: stephenson dt. Nat Med. 2005 Aug;11(8):817-8. doi: 10.1038/nm0805-817b. Nat Med. 2005. PMID: 16079867 No abstract available.

6

Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain.

Kramer RM, Stephenson DT, Roberts EF, Clemens JA. Kramer RM, et al. Among authors: stephenson dt. J Lipid Mediat Cell Signal. 1996 Sep;14(1-3):3-7. doi: 10.1016/0929-7855(96)01501-5. J Lipid Mediat Cell Signal. 1996. PMID: 8906538 Review.

7

Leveraging the regulatory framework to facilitate drug development in Parkinson's disease.

Müller MLTM, Stephenson DT. Müller MLTM, et al. Among authors: stephenson dt. Handb Clin Neurol. 2023;193:347-360. doi: 10.1016/B978-0-323-85555-6.00015-1. Handb Clin Neurol. 2023. PMID: 36803822 Review.

8

Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington's Disease.

Mullin AP, Corey D, Turner EC, Liwski R, Olson D, Burton J, Sivakumaran S, Hudson LD, Romero K, Stephenson DT, Larkindale J. Mullin AP, et al. Among authors: stephenson dt. Clin Transl Sci. 2021 Jan;14(1):214-221. doi: 10.1111/cts.12845. Epub 2020 Aug 25. Clin Transl Sci. 2021. PMID: 32702147 Free PMC article.

9

The distribution of phosphodiesterase 2A in the rat brain.

Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O'Neill SM, Schmidt CJ, Weinberg RJ, Menniti FS. Stephenson DT, et al. Neuroscience. 2012 Dec 13;226:145-55. doi: 10.1016/j.neuroscience.2012.09.011. Epub 2012 Sep 19. Neuroscience. 2012. PMID: 23000621 Free PMC article.

10

Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.

Stephenson DT, Childs MA, Li Q, Carvajal-Gonzalez S, Opsahl A, Tengowski M, Meglasson MD, Merchant K, Emborg ME. Stephenson DT, et al. Cell Transplant. 2007;16(3):229-44. doi: 10.3727/000000007783464704. Cell Transplant. 2007. PMID: 17503735 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results